Skye Bioscience, Inc. 8-K/A

What Happened Skye Bioscience, Inc. (NASDAQ: SKYE) filed a Form 8-K on April 6, 2026 reporting an Item 5.02 disclosure: the departure of directors or certain officers and the election of directors. The filing also discloses an option repricing: the total number of shares of common stock underlying all repriced options is 2,458,158 shares.

Key Details

• Filing date: April 6, 2026 (Form 8-K).
• SEC Item: 5.02 — Departure of Directors or Certain Officers; Election of Directors.
• Option repricing: 2,458,158 shares underlying repriced options in aggregate.
• Ticker: SKYE (Skye Bioscience, Inc.).

Why It Matters

• A reported director/officer change is a governance event investors should note; it can affect board composition or executive leadership depending on who departed or was elected (see the full 8-K for names and effective dates).
• The repricing covers 2,458,158 shares, which is a concrete figure investors can use to assess potential future dilution and changes in stock‑based compensation expense. Review the complete 8-K for terms of the repricing (who received repriced options, new exercise prices and effective dates) to understand the precise impact.